ACHV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACHV is a good buy for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has a positive setup: the price is breaking higher, analyst sentiment is bullish with repeated Buy ratings and a $12-$13 target, and the regulatory/catalyst story remains intact. Given the investor is impatient and does not want to wait for a better entry, this is a direct buy recommendation rather than a hold. The biggest appeal is the upside tied to FDA progress and the fact that Wall Street sees the approval path as relatively de-risked.
ACHV closed at 4.46 after a strong 5.78% regular-session gain, with pre-market and post-market strength as well. MACD histogram is positive and expanding, which supports upward momentum. RSI_6 at 62.37 is constructive and not overbought. Moving averages are converging, suggesting a possible trend transition higher. Price is trading around the pivot (4.501) and above support at 3.978, with nearby resistance at 5.024 and 5.348. Overall, the technical picture is bullish and improving.
["Canaccord initiated Buy coverage with a $13 price target.", "Another analyst report from H.C. Wainwright also rated it Buy with a $12 target.", "Analysts view cytisinicline as a best-in-class nicotine dependence drug with a large unmet need.", "The regulatory path is viewed as de-risked, and the expected FDA action date provides a clear event catalyst.", "The inclusion of Chantix on TrumpRx was viewed by analysts as positive for ACHV\u2019s competitive positioning.", "Price action is strong, with the stock up sharply in the latest session and continuing strength in extended trading.", "Options sentiment is heavily bullish, indicating market participants are positioning for upside."]
["No news in the recent week, so there is no fresh immediate catalyst beyond the existing regulatory setup.", "Revenue is still zero, so the company remains pre-commercial and highly dependent on clinical/regulatory success.", "Net income is still deeply negative at -$14.66 million in the latest quarter.", "EPS remains negative at -0.27.", "Hedge fund and insider trading trends are neutral, showing no strong conviction buying from those groups.", "No recent congress trading data is available."]
In 2025/Q4, ACHV reported revenue of 0, which means the company is still not generating product sales. Net income was -14.662 million, improving 18.62% year over year, but EPS dropped to -0.27, down 25% YoY. This reflects a company still in development mode with losses, though the year-over-year net loss improvement is a modest positive. The latest quarter season is 2025/Q4.
Analyst sentiment is clearly positive. Canaccord initiated coverage twice in April 2026 with a Buy rating and $13 price target, citing cytisinicline as best-in-class and the regulatory path as de-risked. Earlier, H.C. Wainwright also had a Buy rating and $12 target, calling the TrumpRx placement of Chantix a positive for ACHV’s approval prospects. Overall, Wall Street pros are constructive and bullish on the approval/catalyst story, with the main concern being the company’s pre-revenue status rather than the thesis itself.
